Bertis Presents R&D Achievements with Deep Learning-Based Interpretation Tool for Targeted Proteomics Data during Annual Conference of Korean Human Proteome Organization (KHUPO)
- Bertis Bioscience’s CTO Sang-tae Kim visits from the US to speak
- AutoMRM being developed by Bertis is an interpretation tool that dramatically reduces the time required for proteomics data interpretation
- Bertis performs various activities such as participation in a meeting to discuss more uses of proteomics data, setting up a publicity booth to promote its integrative pan-omics analysis solution, PASS
Bertis Inc., a South Korean biotech company dedicated to proteomics-based precision medicine, today announced that it presented Research and Development (R&D) achievements with a new tool to interpret proteomics data during the KHUPO 2022 held at BEXCO in Busan from June 30 to July 1.
Sang-tae Kim, the Chief Technology Officer (CTO) of Bertis Bioscience, the American affiliate of Bertis, shared the latest insights on the company’s R&D achievement, AutoMRM in his lecture titled, ‘Deep Learning and Explainable Artificial Intelligence for Targeted Proteomics’, on June 30.
<Photo: Bertis Bioscience CTO Kim Sang-tae spoke in his lecture, titled ‘Deep Learning and Explainable Artificial Intelligence for Targeted Proteomics’,
during KHUPO 2022 held on June 30.>
CTO Sang-tae Kim said “Bioinformatics and AI technology development is essential to realize the utility of proteomics”
AutoMRM is a deep learning technology-based interpretation tool for targeted proteomics data, which is being developed by Bertis. It is designed to dramatically reduce the time required for data interpretation from 600 hours to less than 1 hour for analysis of the classic MRM (multiple reaction monitoring). The R&D project is led by the bioinformatic expert Sang-tae Kim, who had worked as research scientist at Illumina, the global genome analysis company, and Seer, a leading US proteomics company, and the machine learning team of Bertis.
The research team has continuously updated research results and progress of AutoMRM development with proteomics and bioinformatics experts at major national and international academic conferences. The team’s new insights were presented orally in the 129th General Meeting of the Korean Chemical Society (KCS) which was held in April, and in a poster in the 70th American Society for Mass Spectrometry (ASMS) Conference, held in June.
“As proteomics requires processing of a vast amount of data on human proteome, bioinformatics and AI technology development is essential to realize the utility of proteomics in clinical and healthcare fields,” said Sang-tae Kim. “As a leading proteomic company in Korea, we will remain committed to the development and introduction of innovative analytical tools to invigorate proteomics research and produce research outcomes that can deliver practical benefits to patients and clinicians .”
Various activities by Bertis: Discuss how to expand the use of proteomics data in a meeting with relevant academics and government agencies, Set up a publicity booth during the exhibition
Bertis performed various activities during the 21st Annual Conference of the Korean Human Proteome Organization (KHUPO), which was held under the theme of ‘Proteomics for New Bio-Health’.
On July 1, Seung-man Han, the chief executive officer of Bertis participated in a meeting with officials from the Ministry of Science and ICT and KHUPO to discuss how to expand the use of proteomics data in national bio data R&D projects. The company also operated a publicity booth on June 30 and July 1 to introduce PASS (Pan-omics Analysis Service & Service), a platform for integrative analysis of pan-omics (multi-omics) data.
<Photo: Bertis set up a booth to promote its integrative pan-omics analysis solution PASS
during the 21st Annual Conference of the Korean Human Proteome Organization (KHUPO) held from June 30 to July 1.>
“At this conference, we were able to see remarkable growth of proteomics research in Korea and noticeable research achievements from Korean researchers,” said Seung-man Han. “As a member of the global proteomics community and Korea’s leading proteomics company that has succeeded in commercializing proteomics-based solutions, we will continue to work at the forefront to promote the field of proteomics and enhance cooperation.”
Bertis has discovered biomarkers for cancer and other major disorders and provided diagnostic and analysis solutions based on the combination of proteomics and bioinformatics. Bertis has a track record of successful commercialization of proteomics technology through MASTOCHECK, the world’s first proteomics-based blood test for early breast cancer detection, and PASS (Pan-omics Analysis Service & Service), a platform for integrative analysis of pan-omics (multi-omics) data. The company is also conducting research on early diagnosis solutions for pancreatic cancer and ovarian cancer.